BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 04, 2014
 |  BioCentury  |  Emerging Company Profile

Myelo: Preventing neutropenia

Myelo developing alternative to G-CSF for chemotherapy-induced neutropenia

Myelo Therapeutics GmbH is developing a small molecule that could provide a cheaper and safer alternative to standard of care G-CSF to prevent and to treat chemotherapy-induced neutropenia.

Neutropenia is a decrease in levels of the neutrophil subset of white blood cells required to fight infection. It is caused by diseases or drugs, including chemotherapy, that impair neutrophil production in the bone marrow or destroy neutrophils in circulation.

"In general, chemotherapy-induced neutropenia resolves itself after treatment," co-Managing Director Till Erdmann said. "The problem is that during treatment, patients are susceptible to infections that could be deadly due to the immune suppression. Any problem like this can also be disruptive to the treatment, decreasing the efficacy of the anti-cancer therapy."

In the U.S. and Europe, granulocytic colony stimulating factor (G-CSF) is used prophylactically only in high risk patients and as a therapeutic once neutropenia is detected. It works by stimulating production of new neutrophils in the bone marrow.

According to Erdmann, G-CSF's...

Read the full 790 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >